THAR
Tharimmune Inc.
NASDAQ: THAR · HEALTHCARE · BIOTECHNOLOGY
$3.23
+3.53% today
Updated 2026-04-30
Market cap
$177.09M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.68
Dividend yield
—
52W range
$1 – $9
Volume
0.6M
WallStSmart proprietary scores
17
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$5.00
+54.80%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-1.86M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-2.21M | $-8.47M | $-9.32M | $-12.20M | $-2.10M |
| EPS | — | — | — | — | $-3.68 |
| Free cash flow | $-1.09M | $-6.56M | $-7.30M | $-10.90M | $-1.86M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Tharimmune Inc. trades at $3.23. Our Smart Value Score of 17/100 indicates the stock is weak.
Frequently asked questions
What is Tharimmune Inc.'s stock price?
Tharimmune Inc. (THAR) trades at $3.23.
Is Tharimmune Inc. overvalued?
Smart Value Score 17/100 (Grade F, Strong Sell).
What is the price target of Tharimmune Inc. (THAR)?
The analyst target price is $5.00, representing +54.8% upside from the current price of $3.23.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-2.25%
Beta1.45
50D MA$3.23
200D MA$2.60
Shares out0.04B
Float0.03B
Short ratio—
Avg volume0.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—